Flubrotizolam

Flubrotizolam is a synthetic thienotriazolodiazepine and a designer benzodiazepine related to etizolam and brotizolam. It was originally described in patent literature in the 1970s and 1980s, but did not become prominent until it appeared on the European illicit drug market in 2021. Published information about its pharmacology and toxicity remains limited.

Chemistry and history

Flubrotizolam belongs to the thienotriazolodiazepine group. It is structurally similar to etizolam and deschloroetizolam, but has a bromine substituent on the thiophene-containing ring system. It is also related to brotizolam, a medicine with sedative and hypnotic properties.

The substance was formally notified to the European Early Warning System in 2021. It was identified in counterfeit tablets sold as Xanax-type products, including tablets marked “FANAX” that were seized in several European countries. The European Drugs Agency described its appearance in the illicit market as part of the wider spread of counterfeit benzodiazepine medicines (EUDA, New psychoactive substances: 25 years of early warning and response in Europe).

Pharmacology

There are few direct studies of flubrotizolam’s pharmacological activity. Based on its structural similarity to other thienodiazepines, it is expected to act at the benzodiazepine site of the GABA_A receptor, enhancing the inhibitory effects of GABA. A 2024 UK Advisory Council report describes potent sedative and anxiolytic effects in available reports, but notes that published pharmacological evidence is scarce (ACMD, 2024 update).

Metabolism

A study using pooled human hepatocytes identified several flubrotizolam metabolites. The main pathways included hydroxylation, followed by glucuronidation or sulfation. Six metabolites were observed after incubation, including α-hydroxy- and 6-hydroxy-flubrotizolam and their conjugates. These findings provide potential markers for forensic detection, but do not establish the duration of effects or the clinical significance of each metabolite (Carlier and colleagues, 2024).

Reported effects

Reports describe flubrotizolam as a sedative-hypnotic with anxiolytic properties. Reliable human evidence is too scarce to establish a consistent account of its effects. The available descriptions are largely based on its chemical relationship to brotizolam and other benzodiazepines rather than controlled studies of flubrotizolam itself.

Expected effects of GABA_A modulation include reduced anxiety, drowsiness, muscle relaxation and impaired coordination. Memory impairment and slowed responses are also plausible, but their frequency and severity have not been established for this compound.

Toxicity and research limitations

No detailed clinical case series has established the acute toxic range, dependence potential or long-term effects of flubrotizolam. Its presence in counterfeit tablets makes exposure difficult to assess, since the contents and strength of products may not match their labels.

As with other benzodiazepines, combining it with opioids, alcohol or other central nervous system depressants may intensify sedation and respiratory depression. This risk is a class-related concern; compound-specific interaction studies are not available.

Related compounds

Flubrotizolam is related to Etizolam, Deschloroetizolam, Metizolam and Brotizolam. These compounds share parts of the thienodiazepine structure, but their pharmacological properties should not be assumed to be identical.